Hand-foot skin reaction (HFSR) and overall survival (OS) in the phase 3 RESORCE trial of regorafenib for treatment of hepatocellular carcinoma (HCC) progressing on sorafenib.
暂无分享，去创建一个
M. Kudo | J. Bruix | O. Yokosuka | G. Bodoky | G. Meinhardt | P. Ross | Yi‐Hsiang Huang | A. Granito | G. Han | G. Masi | S. Qin | O. Rosmorduc | T. Song | R. Gérolami | P. Merle | V. Breder | J. Bronowicki | I. Ollivier-Hourmand | A. Baumhauer | Lei Xu